Salud financiera de hoja de balance de Aclaris Therapeutics
Salud financiera controles de criterios 6/6
Aclaris Therapeutics tiene un patrimonio de los accionistas total de $157.2M y una deuda total de $0.0, lo que sitúa su ratio deuda-patrimonio en 0%. Sus activos y pasivos totales son $197.4M y $40.2M respectivamente.
Información clave
0%
Ratio deuda-patrimonio
US$0
Deuda
| Ratio de cobertura de intereses | n/a |
| Efectivo | US$128.17m |
| Patrimonio | US$142.01m |
| Total pasivo | US$32.05m |
| Activos totales | US$174.07m |
Actualizaciones recientes sobre salud financiera
We're Keeping An Eye On Aclaris Therapeutics' (NASDAQ:ACRS) Cash Burn Rate
May 03
Here's Why We're Not Too Worried About Aclaris Therapeutics' (NASDAQ:ACRS) Cash Burn Situation
Nov 03We're Hopeful That Aclaris Therapeutics (NASDAQ:ACRS) Will Use Its Cash Wisely
Apr 07Here's Why We're Not Too Worried About Aclaris Therapeutics' (NASDAQ:ACRS) Cash Burn Situation
Dec 21Here's Why We're Not Too Worried About Aclaris Therapeutics' (NASDAQ:ACRS) Cash Burn Situation
Aug 26Companies Like Aclaris Therapeutics (NASDAQ:ACRS) Are In A Position To Invest In Growth
May 28Recent updates
We're Keeping An Eye On Aclaris Therapeutics' (NASDAQ:ACRS) Cash Burn Rate
May 03Aclaris Therapeutics, Inc.'s (NASDAQ:ACRS) Shares Climb 25% But Its Business Is Yet to Catch Up
Mar 07Analysts Have Been Trimming Their Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Price Target After Its Latest Report
Mar 01Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Stock Rockets 26% As Investors Are Less Pessimistic Than Expected
Jan 19Analysts Are Betting On Aclaris Therapeutics, Inc. (NASDAQ:ACRS) With A Big Upgrade This Week
Nov 11Here's Why We're Not Too Worried About Aclaris Therapeutics' (NASDAQ:ACRS) Cash Burn Situation
Nov 03Analysts Have Lowered Expectations For Aclaris Therapeutics, Inc. (NASDAQ:ACRS) After Its Latest Results
Aug 10What You Need To Know About The Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Analyst Downgrade Today
Aug 08Risks To Shareholder Returns Are Elevated At These Prices For Aclaris Therapeutics, Inc. (NASDAQ:ACRS)
Jun 06We're Hopeful That Aclaris Therapeutics (NASDAQ:ACRS) Will Use Its Cash Wisely
Apr 07Here's Why We're Not Too Worried About Aclaris Therapeutics' (NASDAQ:ACRS) Cash Burn Situation
Dec 21Aclaris initiated as a buy at BTIG on potential of zunsemetinib for autoimmune conditions
Oct 06Here's Why We're Not Too Worried About Aclaris Therapeutics' (NASDAQ:ACRS) Cash Burn Situation
Aug 26Aclaris, Lilly ink patent license deal for Olumiant to treat alopecia areata
Aug 25Aclaris Therapeutics gets a new COO
Aug 01Companies Like Aclaris Therapeutics (NASDAQ:ACRS) Are In A Position To Invest In Growth
May 28We're Not Very Worried About Aclaris Therapeutics' (NASDAQ:ACRS) Cash Burn Rate
Dec 14Is Aclaris Therapeutics (NASDAQ:ACRS) Using Too Much Debt?
Aug 25Aclaris Therapeutics (ACRS) Investor Presentation - Slideshow
Jun 08Shareholders Will Probably Not Have Any Issues With Aclaris Therapeutics, Inc.'s (NASDAQ:ACRS) CEO Compensation
May 28Análisis de la situación financiera
Pasivos a corto plazo: Los activos a corto plazo ($128.9M) de ACRS superan a sus pasivos a corto plazo ($31.0M).
Pasivo a largo plazo: Los activos a corto plazo de ACRS ($128.9M) superan a sus pasivos a largo plazo ($9.3M).
Historial y análisis de deuda-patrimonio
Nivel de deuda: ACRS está libre de deudas.
Reducción de la deuda: ACRS no tiene deuda en comparación con hace 5 años, cuando su ratio deuda-patrimonio era de 13.9%.
Hoja de balance
Análisis de cash runway
En el caso de las empresas que de media han sido deficitarias en el pasado, evaluamos si tienen al menos 1 año de cash runway.
Cash runway estable: ACRS tiene suficiente cash runway para más de un año basándose en su flujo de caja libre actual.
Pronóstico de cash runway: ACRS dispone de suficiente cash runway para 2.8 años si el flujo de caja libre sigue creciendo a tasas históricas de 5.7% cada año.